skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Abatacept in the treatment of rheumatoid arthritis

(2365) Views  (463) Full article downloads

Authors: Edward M Vital, Paul Emery

Published Date January 2006 Volume 2006:2(4) Pages 365 - 375
DOI: http://dx.doi.org/10.2147/TCRM.S

Edward M Vital, Paul Emery

Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Leeds, UK

Abstract: Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-á) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

Keywords: abatacept, rheumatoid arthritis, disease-modifying antirheumatic drugs








Readers of this article also read:

Meropenem in the treatment of complicated skin and soft tissue infections
Restless leg syndrome: is it a real problem?
Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Erratum - Intracellular heavy metal nanoparticle storage
Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision
A case of recurrent bloody tears
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK